Composition: Hydrochlorothiazide Tablets IP 50 mg; BP 25 mg; USP 25 mg and 50 mg. Each uncoated tablet contains the stated amount of Hydrochlorothiazide under its corresponding pharmacopoeial standard.
Usage: Management of edema and high blood pressure, as prescribed.
Category: Diuretic Drugs
Therapeutic Category: Thiazide Diuretic / Antihypertensive
SKU: Hydrochlorothiazide Tablets
Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations
Hydrochlorothiazide Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Hydrochlorothiazide (HCTZ) is a thiazide diuretic used in the management of hypertension and selected forms of edema. Healthy Life Pharma Pvt. Ltd. presents uncoated 25 mg and 50 mg formulations under the IP, BP and USP standards identified below. Third-party manufacturing and export enquiries may be submitted through the website.
Manufactured by: Healthy Life Pharma Pvt. Ltd. (WHO-GMP Certified)
Exported by: Healthy Inc (Star Export House)
| Product variant | Composition per uncoated tablet |
|---|---|
| Hydrochlorothiazide Tablets IP 50 mg | Hydrochlorothiazide IP 50 mg |
| Hydrochlorothiazide Tablets BP 25 mg | Hydrochlorothiazide BP 25 mg; excipients q.s. |
| Hydrochlorothiazide Tablets USP 25 mg | Hydrochlorothiazide USP 25 mg |
| Hydrochlorothiazide Tablets USP 50 mg | Hydrochlorothiazide USP 50 mg |
Dosage form: Uncoated tablet. CAS number: 58-93-5. Therapeutic class: Thiazide diuretic / antihypertensive. 12.5 mg: mentioned in the background description but not confirmed in the supplied product compositions. Packaging, shelf life and precise specifications are subject to the approved product dossier.
Consistent HCTZ tablets require appropriate formulation development, control of blending and content uniformity, tablet compression, and dissolution performance. Light and moisture protection should be determined from product-specific stability data. The precise manufacturing method, excipients, production capacity and packaging must be verified for each approved variant.
Quality controls may include identity, assay, uniformity of dosage units, dissolution, related substances and stability studies against the relevant IP, BP or USP monograph and registered specifications. Specific release percentages, assay limits and shelf-life claims should be confirmed using the applicable validated methods and batch documentation.
Hydrochlorothiazide acts in the distal convoluted tubule of the kidney by inhibiting the sodium-chloride cotransporter, increasing urinary sodium and water excretion. It is used to help control high blood pressure and certain types of fluid retention. Other uses, such as nephrogenic diabetes insipidus or prevention of recurrent calcium stones in selected patients, require specialist assessment; evidence and suitability vary.
For pharmaceutical procurement, export or third-party manufacturing enquiries, request the specific batch certificate of analysis, available stability information, product registration status, and relevant quality or regulatory documentation. CTD/ACTD dossiers, FSC, COPP and shipping arrangements should be confirmed for the destination country and exact formulation.
Q: Which strengths are listed?
A: BP and USP 25 mg, plus IP and USP 50 mg uncoated tablets.
Q: Is 12.5 mg available?
A: The description mentions it, but no 12.5 mg composition was provided for confirmation.
Q: Does it increase urination?
A: Yes, increased urination can occur, especially after starting therapy.
Q: Does it lower potassium?
A: It can cause low potassium or sodium. Blood tests and treatment decisions should be guided by a clinician; do not independently start potassium supplements.
Take only as prescribed. Dose and timing depend on the condition, kidney function, other medicines and treatment response. Morning administration is often preferred to reduce nighttime urination. Do not change the dose or stop treatment without medical advice.
Keep in the original, tightly closed container, protected from light and moisture as directed on the approved label. Store out of reach of children. Follow the product-specific labelled temperature limits.